Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–70 of 70 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo two times a day (BID)/three times a day (TID) Clear all
Completed Phase 2 Interventional Results available

Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index

NCT02470403
View directory record Official record
Conditions
Elevated Body Mass Index
Interventions
LIK066, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.

NCT01166425
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Placebo
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
7 Years to 17 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Washington D.C., District of Columbia • South Chicago Heights, Illinois • Psychiatry and Behavioral Sciences, 1010 N Kansas St, Wichita, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Multiple-Dose Pharmacokinetics (PK), and Pharmacodynamic (PD) Effect of NSI-189 Phosphate in Depression Patient Subjects

NCT01520649
View directory record Official record
Conditions
Depression
Interventions
NSI-189 Phosphate, microcrystalline cellulose capsules
Drug
Lead sponsor
Neuralstem Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

NCT00451451
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
BG00012, Placebo, Glatiramer Acetate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
72
States / cities
Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors

NCT03530800
View directory record Official record
Conditions
Trichotillomania, Skin-Picking
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 10, 2026, 1:03 AM EDT
Terminated Phase 2 Interventional Results available

Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease

NCT02730793
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Oral Aztreonam, Nasal Aztreonam, Nasal Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
7 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 10, 2026, 1:03 AM EDT
Recruiting Early Phase 1 Interventional

Safety and Efficacy of Aloe Vera in the Management of the Symptoms of Interstitial Cystitis

NCT04734106
View directory record Official record
Conditions
Interstitial Cystitis, Chronic Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Desert Harvest Aloe Vera Capsules, Placebo Capsules
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Efficacy and Safety of VIT-2763 (Vamifeport) in Subjects With Sickle Cell Disease

NCT04817670
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
VIT-2763 120 mg, VIT-2763 360 mg, VIT-2763 240 mg, Placebo BID, Placebo TID
Drug
Lead sponsor
Vifor (International) Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 3 Interventional Results available

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

NCT00852540
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retpamulin Ointment, 1%, Linezolid
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
2 Months and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 10, 2026, 1:03 AM EDT
Terminated Phase 2 Interventional Results available

High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children

NCT00495521
View directory record Official record
Conditions
Crohn's Disease
Interventions
4-Aminosalicylic acid extended release granules
Drug
Lead sponsor
Jacobus Pharmaceutical
Industry
Eligibility
2 Years to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Interventions Against Insulin Resistance in Pulmonary Arterial Hypertension

NCT03617458
View directory record Official record
Conditions
Pulmonary Artery Hypertension
Interventions
Metformin, Placebo, mHealth Intervention, Usual Care
Drug · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Nashvile, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 3 Interventional

Gabapentin in Treating Peripheral Neuropathy in Cancer Patients Undergoing Chemotherapy

NCT00027963
View directory record Official record
Conditions
Neurotoxicity, Pain
Interventions
gabapentin, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
22
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 1 Interventional

Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

NCT00623649
View directory record Official record
Conditions
HCV Infection
Interventions
VCH 916, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2014 · Synced Oct 10, 2026, 1:03 AM EDT
Terminated Phase 2 Interventional Results available

Combination Pain Therapy in HIV Neuropathy

NCT00863057
View directory record Official record
Conditions
HIV Infections, Peripheral Neuropathy
Interventions
Duloxetine, Duloxetine placebo, Methadone, Methadone placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Diego, California • Torrance, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder

NCT01172275
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
N-Acetylcysteine, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
8 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 4 Interventional

To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses

NCT00648973
View directory record Official record
Conditions
Nasal Congestion
Interventions
Diphenhydramine 50 mg, Diphenhydramine 25 mg, Pseudoephedrine 120 mg
Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
12
States / cities
Austin, Texas • Dallas, Texas • Kerrville, Texas + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 2 Interventional

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

NCT01482403
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, Pegasys, boceprevir, mericitabine, mericitabine placebo, boceprevir placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
7
States / cities
Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement in Healthy Male Volunteers

NCT01962454
View directory record Official record
Conditions
Cachexia
Interventions
Deuterated Water, Testosterone enanthate, Placebo to match testosterone enanthate
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years to 75 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 2 Interventional Results available

Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate

NCT03221257
View directory record Official record
Conditions
Scleroderma, Systemic, Interstitial Lung Disease
Interventions
Pirfenidone (PFD), Placebo (Plac), Mycophenolate Mofetil (MMF)
Drug
Lead sponsor
Michael Roth
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole

NCT00640809
View directory record Official record
Conditions
Bowel Diseases, Inflammatory
Interventions
Celecoxib, Placebo, Ibuprofen plus Omeprazole
Drug · Other
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
408 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
12
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 10, 2026, 1:03 AM EDT
Terminated Phase 2 Interventional

High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease

NCT00417690
View directory record Official record
Conditions
Crohn's Disease
Interventions
4-Aminosalicylic acid, PASER placebo granules
Drug
Lead sponsor
Jacobus Pharmaceutical
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2008 · Synced Oct 10, 2026, 1:03 AM EDT
Completed Phase 2Phase 3 Interventional

Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo

NCT01670032
View directory record Official record
Conditions
Impetigo
Interventions
Experimental: CD07223 1.5 % Topical Gel BID, Experimental: CD07223 1.5% Topical Gel TID, Placebo Comparator: CD07223 vehicle gel BID, Placebo Comparator: CD07223 vehicle gel TID
Drug
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Industry
Eligibility
2 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Bell Gardens, California • Boca Raton, Florida • Hialeah, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Oct 10, 2026, 1:03 AM EDT